Apr 27, 2021 / 01:00PM GMT
Operator
Good day, and welcome to the bioMérieux First Quarter 2021 Business Review. Today's conference is being recorded. At this time, I would like to turn the conference over to Franck Admant. Please go ahead, sir.
Franck Admant - bioMérieux S.A.-Director of IR
Thank you, Kim. Good afternoon, and thank you for joining us to review bioMérieux's performance for the first quarter of 2021. As usual, I am online with Alexandre Mérieux, Chairman and CEO; as well as Guillaume Bouhours, the CFO. Before handing the call over to Alexandre for preliminary remarks, please note that this conference call will include forward-looking statements.
I would like to remind you of the usual disclaimer saying that forward-looking statements are based entirely and partially on assessments or judgments that may change or be modified. Due to uncertainties and risks related to the company's environment, notably we described it in the 2020 registration document, including but not limited to, economic conditions, financial exposure to currency
Q1 2021 Biomerieux SA Business Review Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers